RxDoctor Payments Data

Bret Witter, MD

Cardiovascular Disease · Los Alamitos, CANPI 1396783387

Payments from drug & device makers

$1,874in general payments, 2019–2025

Across 94 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$316
  • Johnson & Johnson$306
  • Atricure, Inc.$162
  • Boston Scientific$161
  • Amgen$160
  • Pfizer$108
  • plus $662 from 19 others

What the payments were for

  • Food & beverage$1,874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,874 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$429,439
Medicare patients
1,452
Services billed
7,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban702$794,672
XareltoRivaroxaban315$320,290
VyndamaxTafamidis12$260,159
EntrestoSacubitril/Valsartan89$98,332
FarxigaDapagliflozin Propanediol105$97,055
Repatha SureclickEvolocumab58$67,573
Praluent PenAlirocumab33$33,454
JardianceEmpagliflozin21$29,980
MultaqDronedarone Hcl21$28,951
Repatha SyringeEvolocumab30$28,887
BrilintaTicagrelor14$13,294
Metoprolol Succinate558$8,679
Ezetimibe194$6,039
Rosuvastatin Calcium260$4,418
Dabigatran EtexilateDabigatran Etexilate Mesylate11$3,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$108$1,054,831714 claims
Johnson & JohnsonXarelto$306$320,290315 claims
NovartisEntresto$316$98,33289 claims
Sanofi-aventis U.S. LLCMultaq$46$28,95121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →